PD-L1 Biomarkers

Roche, Bristol Myers Squibb Partner on Digital Pathology Algorithms, Assays for Cancer Diagnosis

Agilent Gets CE Mark for Expanded Use of PD-L1 CDx in Triple-Negative Breast Cancer

Labcorp, CCORN Ink Partnership to Address Precision Oncology Disparities

FDA Approves Regeneron, Sanofi's Libtayo With Agilent PD-L1 CDx in Frontline NSCLC

Diaceutics, Alva10 Gathering Evidence Base for Improving PD-L1 Test Reimbursement

FDA Approves Merck's Keytruda, Agilent CDx in PD-L1-High Triple-Negative Breast Cancer

Inspirata, Flagship Bio Enter Digital Pathology Pact

Biodesix, Addario Lung Cancer Institute Studying PIR Test Ability to Predict Immunotherapy Response

Roche Digital Pathology Algorithm for NSCLC Receives CE Mark

Genentech's Tecentriq Receives First-Line FDA Approval for High PD-L1-Expressing Lung Cancer

Agilent Keytruda CDx Gets CE IVD Mark in Europe

Merck, Promega Collaborate to Develop MSI CDx for Keytruda

Agilent Technologies PD-L1 IHC Assay Approved by China Regulators

Roche's Tecentriq Nabs EC Approval in Triple-Negative Breast Cancer, Ventana Expands Use of CDx

IncellDx Inks Chinese Collaboration, Distribution Agreements

FDA Approves Expanded Use of Agilent CDx for Keytruda in Esophageal Cancer

FDA Approves Expanded Use of Agilent CDx for Keytruda in Head and Neck Cancer

FDA Approves Expanded Use of Agilent CDx for Keytruda in Lung Cancer